Biotemed says Genis agreement creates new opportunities

Biotemed chairman Nie Renke says the Chinese biotechnology company’s agreement with Genis creates significant opportunities, Morgunblaðið reported. The agreement was signed at Biotemed’s headquarters in Qingdao, in the presence of Icelandic Foreign Minister Þorgerður Katrín Gunnarsdóttir and an Icelandic business delegation.

Nie said his work in recent years had focused on Chinese marine biotechnology and bringing its products to international markets. He said he aimed to turn more than 40 years of research by a team led by Liu Wanshun, a professor at Ocean University of China, into high-quality products for medical and healthcare use worldwide.

Biotemed was founded in Qingdao in 2006, based on a city initiative called the Blue Medicine Bank. Its technology draws on research into modified chitosan, a biomaterial derived from seafood. The company initially focused on medical devices for stopping bleeding and helping wounds heal.

Nie said Biotemed had since expanded into six main business areas: healthcare, consumer products, military medicine, aesthetic medicine and recovery, veterinary medicine, and dietary supplements. He said several of its products had replaced imported products at Chinese healthcare institutions and were used in a range of surgical procedures.

Biotemed also makes products for oral hygiene and infant care. Nie said its products could stop arterial bleeding with pressure within 30 seconds and were designed for emergencies including battlefield first aid and rescue operations. He said the company’s products and services were available in 32 countries and regions.

Nie said the company’s aesthetic medicine offering covers preparation, protection during treatment, recovery and home care, while its veterinary business adapts its medical chitosan technology and treatment methods for pet health.